Leishmaniasis (Kala-Azar) – Pipeline Review, H2 2020

Global Markets Direct’s, ‘Leishmaniasis (Kala-Azar) – Pipeline Review, H2 2020’, provides an overview of the Leishmaniasis (Kala-Azar) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Leishmaniasis (Kala-Azar), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Leishmaniasis (Kala-Azar) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Leishmaniasis (Kala-Azar)

– The report reviews pipeline therapeutics for Leishmaniasis (Kala-Azar) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Leishmaniasis (Kala-Azar) therapeutics and enlists all their major and minor projects

– The report assesses Leishmaniasis (Kala-Azar) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Leishmaniasis (Kala-Azar)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Leishmaniasis (Kala-Azar)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Leishmaniasis (Kala-Azar) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

ABIONYX Pharma SA

Acea Biotech Inc

Biokawthar Technologies SAS

BioLingus AG

Daiichi Sankyo Co Ltd

DetectoGen Inc

Eisai Co Ltd

GlaxoSmithKline Plc

iCo Therapeutics Inc

Immune Modulation Inc

Impetis Biosciences Ltd

Laboratorios LETI SLU

Macrophage Therapeutics Inc

ManRos Therapeutics

Matinas BioPharma Holdings Inc

MedC Biopharma Ltd

Mind Medicine Inc

Molecular Targeting Technologies Inc

Mycosynthetix Inc

NanoCliq LLC

Nanomerics Ltd

Novartis AG

Oblita Therapeutics BVBA

Pai Life Sciences Inc

Pfizer Inc

Pharos I&BT Co Ltd

Rakta Therapeutics Inc

Synstar Japan Co Ltd

Table of Contents

Table of Contents

Introduction

Leishmaniasis - Overview

Leishmaniasis - Therapeutics Development

Leishmaniasis - Therapeutics Assessment

Leishmaniasis - Companies Involved in Therapeutics Development

Leishmaniasis - Drug Profiles

Leishmaniasis - Dormant Projects

Leishmaniasis - Discontinued Products

Leishmaniasis - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Leishmaniasis (Kala-Azar), H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020 (Contd..1), H2 2020

Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020 (Contd..1), H2 2020

Products under Development by Universities/Institutes, H2 2020

Products under Development by Universities/Institutes, H2 2020 (Contd..1), H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Leishmaniasis (Kala-Azar) – Pipeline by ABIONYX Pharma SA, H2 2020

Leishmaniasis (Kala-Azar) – Pipeline by Acea Biotech Inc, H2 2020

Leishmaniasis (Kala-Azar) – Pipeline by Biokawthar Technologies SAS, H2 2020

Leishmaniasis (Kala-Azar) – Pipeline by BioLingus AG, H2 2020

Leishmaniasis (Kala-Azar) – Pipeline by Daiichi Sankyo Co Ltd, H2 2020

Leishmaniasis (Kala-Azar) – Pipeline by DetectoGen Inc, H2 2020

Leishmaniasis (Kala-Azar) – Pipeline by Eisai Co Ltd, H2 2020

Leishmaniasis (Kala-Azar) – Pipeline by GlaxoSmithKline Plc, H2 2020

Leishmaniasis (Kala-Azar) – Pipeline by iCo Therapeutics Inc, H2 2020

Leishmaniasis (Kala-Azar) – Pipeline by Immune Modulation Inc, H2 2020

Leishmaniasis (Kala-Azar) – Pipeline by Impetis Biosciences Ltd, H2 2020

Leishmaniasis (Kala-Azar) – Pipeline by Laboratorios LETI SLU, H2 2020

Leishmaniasis (Kala-Azar) – Pipeline by Macrophage Therapeutics Inc, H2 2020

Leishmaniasis (Kala-Azar) – Pipeline by ManRos Therapeutics, H2 2020

Leishmaniasis (Kala-Azar) – Pipeline by Matinas BioPharma Holdings Inc, H2 2020

Leishmaniasis (Kala-Azar) – Pipeline by MedC Biopharma Ltd, H2 2020

Leishmaniasis (Kala-Azar) – Pipeline by Mind Medicine Inc, H2 2020

Leishmaniasis (Kala-Azar) – Pipeline by Molecular Targeting Technologies Inc, H2 2020

Leishmaniasis (Kala-Azar) – Pipeline by Mycosynthetix Inc, H2 2020

Leishmaniasis (Kala-Azar) – Pipeline by NanoCliq LLC, H2 2020

Leishmaniasis (Kala-Azar) – Pipeline by Nanomerics Ltd, H2 2020

Leishmaniasis (Kala-Azar) – Pipeline by Novartis AG, H2 2020

Leishmaniasis (Kala-Azar) – Pipeline by Oblita Therapeutics BVBA, H2 2020

Leishmaniasis (Kala-Azar) – Pipeline by Pai Life Sciences Inc, H2 2020

Leishmaniasis (Kala-Azar) – Pipeline by Pfizer Inc, H2 2020

Leishmaniasis (Kala-Azar) – Pipeline by Pharos I&BT Co Ltd, H2 2020

Leishmaniasis (Kala-Azar) – Pipeline by Rakta Therapeutics Inc, H2 2020

Leishmaniasis (Kala-Azar) – Pipeline by Synstar Japan Co Ltd, H2 2020

Leishmaniasis (Kala-Azar) – Dormant Projects, H2 2020

Leishmaniasis (Kala-Azar) – Dormant Projects, H2 2020 (Contd..1), H2 2020

Leishmaniasis (Kala-Azar) – Dormant Projects, H2 2020 (Contd..2), H2 2020

Leishmaniasis (Kala-Azar) – Discontinued Products, H2 2020

List of Figures

List of Figures

Number of Products under Development for Leishmaniasis (Kala-Azar), H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Number of Products by Top 10 Targets, H2 2020

Number of Products by Stage and Top 10 Targets, H2 2020

Number of Products by Top 10 Mechanism of Actions, H2 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020

Number of Products by Top 10 Routes of Administration, H2 2020

Number of Products by Stage and Top 10 Routes of Administration, H2 2020

Number of Products by Top 10 Molecule Types, H2 2020

Number of Products by Stage and Top 10 Molecule Types, H2 2020

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports